Therapeutic Cancer Vaccines: Current Status and Moving ForwardSCHLOM, Jeffrey.Journal of the National Cancer Institute. 2012, Vol 104, Num 8, pp 599-613, issn 0027-8874, 15 p.Article

Cancer VaccinesSCHLOM, Jeffrey; HODGE, James W.Seminars in oncology. 2012, Vol 39, Num 3, issn 0093-7754, 126 p.Serial Issue

Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8⁺ T cellsSIXUN YANG; SCHLOM, Jeffrey.Cancer immunology and immunotherapy. 2009, Vol 58, Num 4, pp 503-515, issn 0340-7004, 13 p.Article

Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cellsSIXUN YANG; TSANG, Kwong-Yok; SCHLOM, Jeffrey et al.Clinical cancer research. 2005, Vol 11, Num 15, pp 5603-5615, issn 1078-0432, 13 p.Article

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity : Effects of Docetaxel on Immune EnhancementGARNETT, Charlie T; SCHLOM, Jeffrey; HODGE, James W et al.Clinical cancer research. 2008, Vol 14, Num 11, pp 3536-3544, issn 1078-0432, 9 p.Article

Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptidePALENA, Claudia; SCHLOM, Jeffrey; TSANG, Kwong-Yok et al.Clinical cancer research. 2003, Vol 9, Num 5, pp 1616-1627, issn 1078-0432, 12 p.Article

Sipuleucel-T for the Treatment of Advanced Prostate CancerFROHLICH, Mark W.Seminars in oncology. 2012, Vol 39, Num 3, pp 245-252, issn 0093-7754, 8 p.Article

Vaccines for Melanoma and Renal Cell CarcinomaKAUFMAN, Howard L.Seminars in oncology. 2012, Vol 39, Num 3, pp 263-275, issn 0093-7754, 13 p.Article

Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenHODGE, James W; HIGGINS, Jack; SCHLOM, Jeffrey et al.Vaccine. 2009, Vol 27, Num 33, pp 4475-4482, issn 0264-410X, 8 p.Article

Cancer vaccines : Moving beyond current paradigmsSCHLOM, Jeffrey; ARLEN, Philip M; GULLEY, James L et al.Clinical cancer research. 2007, Vol 13, Num 13, pp 3776-3782, issn 1078-0432, 7 p.Article

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responsesKUDO-SAITO, Chie; SCHLOM, Jeffrey; HODEE, James W et al.Clinical cancer research. 2005, Vol 11, Num 6, pp 2416-2426, issn 1078-0432, 11 p.Article

Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory moleculesKUDO-SAITO, Chie; SCHLOM, Jeffrey; HODGE, James W et al.Clinical cancer research. 2004, Vol 10, Num 3, pp 1090-1099, issn 1078-0432, 10 p.Article

Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activityAARTS, Wilhelmina M; SCHLOM, Jeffrey; HODGE, James W et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5770-5777, issn 0008-5472, 8 p.Article

Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3)SHANKAR, Pragyna; SCHLOM, Jeffrey; HODGE, James W et al.Vaccine. 2001, Vol 20, Num 5-6, pp 744-755, issn 0264-410XArticle

Clinical Evaluation of TRICOM Vector Therapeutic Cancer VaccinesMADAN, Ravi A; BILUSIC, Marijo; HEERY, Christopher et al.Seminars in oncology. 2012, Vol 39, Num 3, pp 296-304, issn 0093-7754, 9 p.Article

Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cellsPALENA, Claudia; MINGZHU ZHU; SCHLOM, Jeffrey et al.Blood. 2004, Vol 104, Num 1, pp 192-199, issn 0006-4971, 8 p.Article

Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunityGREINER, John W; ZEYTIN, Hasan; ANVER, Miriam R et al.Cancer research (Baltimore). 2002, Vol 62, Num 23, pp 6944-6951, issn 0008-5472, 8 p.Article

Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical TrialTHOMAS, Sheeba K; KWAK, Larry W.Seminars in oncology. 2012, Vol 39, Num 3, pp 253-262, issn 0093-7754, 10 p.Article

Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4⁺ T cells in the absence of APCsJUN ZHOU; TAGAYA, Yutaka; TOLOUEI-SEMNANI, Roshanak et al.Blood. 2005, Vol 105, Num 8, pp 3238-3246, issn 0006-4971, 9 p.Article

Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursorsRAD, Ariel N; SCHLOM, Jeffrey; HODGE, James W et al.Critical reviews in oncology/hematology. 2001, Vol 39, Num 1-2, pp 43-57, issn 1040-8428Conference Paper

Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate CancerGULLEY, James L; MADAN, Ravi A; HEERY, Christopher R et al.Cancer immunology research (Print). 2014, Vol 2, Num 2, pp 133-141, issn 2326-6066, 9 p.Article

Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor PrognosisPALENA, Claudia; ROSELLI, Mario; JOCHEMS, Caroline et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 5, issn 0027-8874, dju054.1-dju054.12Article

Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer ImmunotherapyOSADA, Takuya; MORSE, Michael A; HOBEIKA, Amy et al.Seminars in oncology. 2012, Vol 39, Num 3, pp 305-310, issn 0093-7754, 6 p.Article

Strategies to Use Immune Modulators in Therapeutic Vaccines Against CancerBERZOFSKY, Jay A; TERABE, Masaki; WOOD, Lauren V et al.Seminars in oncology. 2012, Vol 39, Num 3, pp 348-357, issn 0093-7754, 10 p.Article

New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapyCEREDA, Vittore; POOLE, Diane J; SCHLOM, Jeffrey et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 1, pp 63-71, issn 0340-7004, 9 p.Article